Overview

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

A randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-323 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to assess the antiviral effect of EDP-323 compared to a placebo control in the respiratory syncytial virus challenge model.

Phase:

Phase 2

Details

Lead Sponsor:

Enanta Pharmaceuticals, Inc

Collaborator:

hVIVO Services Limited